• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Assessment of left ventricular size and function by 3-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
ConclusionsThe echocardiography platform and analysis software significantly affect the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Assessment of left ventricular size and function by three-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
Conclusions The echocardiography platform and analysis software significantly affects the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - May 28, 2018 Category: Cardiology Source Type: research

Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusions In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research

The Optimal Anti-Coagulation for Enhanced-Risk Patients Post –Catheter Ablation for Atrial Fibrillation (OCEAN) trial
The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure. Methods/design A prospective, multicenter, open-label, randomized trial with blinded assessment of outcomes is under way (NCT02168829). Atrial fibrillation patients with at least 1 stroke risk factor (as defined by the CHA2DS2-VASc score) and without known atrial arrhythmia recurrences for at least 12 months after ablation ar...
Source: American Heart Journal - January 17, 2018 Category: Cardiology Source Type: research

The Optimal Anti-Coagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial
Discussion The OCEAN trial is a multicenter randomized controlled trial evaluating two antithrombotic treatment strategies for patients with risk factors for stroke after apparently successful AF ablation. We hypothesize that rivaroxaban will reduce the occurrence of clinically overt stroke, systemic embolism, and covert stroke when compared to ASA alone.
Source: American Heart Journal - December 9, 2017 Category: Cardiology Source Type: research

Role of Doppler Echocardiography for Cardiac Output Assessment in Fontan Patients
Conclusion Doppler SVI correlated with CMRI SVI in patients with systemic LV and systemic RV. The association between output measures (SVI and CI) and FAD were seen only in single LV patients (single RV patients not assessed for this outcome due to small numbers). An association between low Doppler CI and Fontan failure was suggested in a small number of single LV patients.
Source: American Heart Journal - September 22, 2017 Category: Cardiology Source Type: research

Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
Publication date: Available online 24 April 2017 Source:American Heart Journal Author(s): Renato D. Lopes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher B. Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens C. Nielsen, David Conen, Stefan H. Hohnloser, Georges H. Mairesse, Philippe Mabo, A. John Camm, Jeffrey S. Healey Device-detected subclinical atrial fibrillation (AF) refers to infrequent, short-lasting, asymptomatic AF that is detected only with long-term continuous monitoring. Subclinical AF is common and associated with an increased risk of stroke; however, the risk of stroke with subclinical AF ...
Source: American Heart Journal - April 24, 2017 Category: Cardiology Source Type: research

Left ventricular mass-geometry and silent cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) Study
Conclusions LV hypertrophy, both with eccentric or concentric pattern, was significantly associated with subclinical cerebrovascular disease in a multiethnic stroke-free general population. LV geometric patterns may carry different risks for silent cerebrovascular disease in different sex, age, race-ethnic, and body size subgroups.
Source: American Heart Journal - December 20, 2016 Category: Cardiology Source Type: research

Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring—Find-AFRANDOMISED —rationale and design
Background: Detecting paroxysmal atrial fibrillation (AF) in patients with ischemic strokes presenting in sinus rhythm is challenging because episodes are often short, occur randomly, and are frequently asymptomatic. If AF is detected, recurrent thromboembolism can be prevented efficiently by oral anticoagulation. Numerous uncontrolled studies using various electrocardiogram (ECG) devices have established that prolonged ECG monitoring increases the yield of AF detection, but most established procedures are time-consuming and costly. The few randomized trials are mostly limited to cryptogenic strokes. The optimal method, du...
Source: American Heart Journal - July 7, 2014 Category: Cardiology Authors: Mark Weber-Krüger, Götz Gelbrich, Raoul Stahrenberg, Jan Liman, Pawel Kermer, Gerhard F. Hamann, Joachim Seegers, Klaus Gröschel, Rolf Wachter, Find-AFRANDOMISED investigators Tags: Trial Designs Source Type: research

Scar tissue–guided left ventricular lead placement for cardiac resynchronization therapy in patients with ischemic cardiomyopathy: An acute pressure-volume loop study
Background: Response to cardiac resynchronization therapy (CRT) is hampered by the extent and location of left ventricular (LV) scar tissue. It is commonly advised to avoid scar tissue while placing the LV lead. However, whether individual patients benefit from this strategy remains unclear.Methods: Thirty-two CRT candidates with ischemic cardiomyopathy were enrolled from 2 successive clinical trials (TBS and E-pot study). Magnetic resonance imaging with late contrast enhancement was performed to assess location, degree and transmurality of LV scar tissue. Patients underwent invasive pressure-volume loop measurements to as...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Gerben Jan de Roest, LiNa Wu, Carel C. de Cock, Matthijs L. Hendriks, Peter Paul H.M. Delnoy, Albert C. van Rossum, Cornelis P. Allaart Tags: Heart Failure Source Type: research

INtensive versus Standard Ambulatory Blood Pressure Lowering to Prevent Functional DeclINe In The ElderlY (INFINITY)
Reductions in mobility and cognitive function linked to accrual of brain microvascular disease related white matter hyperintensities (WMHs) on magnetic resonance imaging can occur in older hypertensive patients in as little as 2 years. We have designed a trial evaluating 2 levels of ambulatory blood pressure (ABP) control in individuals with normal or mildly impaired mobility and cognition who have detectable cerebrovascular disease (>0.5% WMH fraction of intracranial volume) on functional outcomes. The study is a prospective randomized, open-label trial with blinded end points, in patients ages ≥75 years with elevated 2...
Source: American Heart Journal - January 7, 2013 Category: Cardiology Authors: William B. White, Ravi Marfatia, Julia Schmidt, Dorothy B. Wakefield, Richard F. Kaplan, Richard W. Bohannon, Charles B. Hall, Charles R. Guttmann, Nicola Moscufo, Douglas Fellows, Leslie Wolfson Tags: Trial Design Source Type: research